Uveal Melanoma is an indication for drug development with over 80 pipeline drugs currently active. According to GlobalData, preregistered drugs for Uveal Melanoma have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Uveal Melanoma compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Uveal Melanoma overview
Uveal melanoma, the most common intraocular tumor, is a disease in which malignant (cancer) cells are found in the part of the eye called the uvea. The uvea contains cells called melanocytes. When these cells become cancerous, the cancer is called a melanoma. Symptoms include a dark spot on the iris, glaucoma, eye pain, and eye redness. Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. Treatment includes surgery, radiation, and proton therapy.
See Also:
For a complete picture of PTSR and LoA scores for drugs in Uveal Melanoma, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.